Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 65 years or older
- People who have been newly diagnosed with multiple myeloma that meets specific international diagnostic standards, including having a measurable amount of the disease detected through blood or urine tests
- People whose multiple myeloma has caused at least one of the following: high calcium levels in the blood, reduced kidney function, low red blood cell levels (anaemia), or bone damage — or who meet certain other markers of disease severity detected through scans or lab tests
- People who are expected to live for more than 3 months
- People who do not have an active infectious disease at the time of joining
- People who are able to understand what the study involves and are willing to take part in both the treatment and follow-up stages
- People who have signed a consent form agreeing to take part (this may be signed by the patient or a close family member)
Who may not be able to join:
- People who currently have active hepatitis B, hepatitis C, or other immune deficiency conditions (whether inherited or acquired)
- People who have moderate or severe nerve damage or nerve pain in their hands or feet (Grade 2 or higher), unless it is caused by pressure from disease outside the bone marrow
- People diagnosed with plasma cell leukaemia, or who have disease that has spread outside the bone marrow to soft tissues not involving bone
- People who have had a serious blood clotting event before starting treatment
- People who have moderate or severe nerve damage in the hands or feet (Grade 2 or higher) before treatment begins (confirm with trial site, as this overlaps with criterion above)
- People whose liver is not functioning properly, based on specific blood test results showing liver enzyme levels at 2.5 times or more above the normal range
- People whose bilirubin levels (a marker of liver function) are 1.5 times or more above the normal range
- People who have had major surgery within 30 days before joining the trial
- People with epilepsy, dementia, or other conditions affecting mental function that require medication and make it difficult to understand or follow the study requirements
- People with serious physical or mental health conditions that, in the opinion of the medical team, may interfere with taking part in the study
- People with drug or substance use issues, or medical, psychological, or social circumstances that could affect their participation or the reliability of study results
- People who are currently taking part in another clinical trial involving an experimental treatment
- People who are pregnant or breastfeeding
- People whom the trial investigator considers unsuitable for enrolment for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lijuan Chen, The First Affiliated Hospital with Nanjing Medical University
Phone: +86-025-68306091
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free Survival (PFS); MRD Negative Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.